尼塞韦单抗对呼吸道合胞病毒估计有效性的研究
本研究为检测阴性病例对照研究,利用耶鲁纽黑文健康系统2023年10月1日至2024年5月9日数据,纳入3090名符合尼塞韦单抗接种条件的婴儿,其中RSV阳性病例680例、阴性对照2410例。尼塞韦单抗接种率为10.7%(330例)。调整后估计有效性对需医疗关注的RSV感染为68.4%(95%CI 50.3%-80.8%),对门诊就诊为61.6%(35.6%-78.6%),对住院为80.5%(52.0%-93.5%),对重症RSV疾病最高为84.6%(58.7%-95.6%)。有效性从免疫后2周的79.3%下降至14周的54.8%,但仍显著;不同剂量间无实质差异。RSV流行高峰期间对全因下呼吸道感染有效性为49.4%(10.7%-72.9%),对全因下呼吸道感染相关住院为79.1%(27.6%-94.9%);2024年2月至5月对其他病毒所致下呼吸道感染的有效性可忽略。
要点
- 尼塞韦单抗对需医疗关注的RSV感染调整后估计有效性为68.4%(95%CI 50.3%-80.8%),对RSV住院为80.5%(52.0%-93.5%)。
- 对重症RSV疾病(需高流量氧疗或ICU入住)估计有效性最高,为84.6%(95%CI 58.7%-95.6%)。
- 有效性从免疫后2周的79.3%(63.4%-90.6%)下降至14周的54.8%(16.3%-74.7%),但仍保持显著。
- 不同剂量间估计有效性无实质差异。
- RSV流行高峰期间对全因下呼吸道感染有效性为49.4%(10.7%-72.9%),对全因下呼吸道感染相关住院为79.1%(27.6%-94.9%);2024年2月至5月对 broader outcomes 的有效性可忽略。
适用人群与场景
- 纳入标准:2023年10月1日至2024年5月9日在耶鲁纽黑文健康系统(住院、门诊和急诊)接受RSV聚合酶链反应检测且符合尼塞韦单抗接种条件的婴儿。
- 场景:住院、门诊和急诊。
诊断标准与关键阈值
- 检测阴性病例对照设计:RSV聚合酶链反应阳性为病例,阴性为对照。
- 重症RSV疾病定义:需要高流量氧疗或入住重症监护室。
研究设计与关键结果
- 研究类型:检测阴性病例对照研究;样本量3090例婴儿(男性1722例,57.3%;检测时中位年龄6.7个月,IQR 3.6-9.7个月);RSV阳性病例680例(22.0%),阴性对照2410例(78.0%)。
- 尼塞韦单抗接种率10.7%(330例),其中RSV阳性病例21例、RSV阴性对照309例。
- 调整后估计有效性:对需医疗关注的RSV感染为68.4%(95%CI 50.3%-80.8%),对门诊就诊为61.6%(35.6%-78.6%),对住院为80.5%(52.0%-93.5%)。
- 对重症RSV疾病的估计有效性最高,为84.6%(95%CI 58.7%-95.6%)。
- 估计有效性从免疫后2周的79.3%(95%CI 63.4%-90.6%)下降至14周的54.8%(95%CI 16.3%-74.7%),但仍显著。
- 不同剂量间估计有效性无实质差异。
- RSV流行高峰期间,对全因下呼吸道感染的估计有效性为49.4%(95%CI 10.7%-72.9%),对全因下呼吸道感染相关住院为79.1%(95%CI 27.6%-94.9%)。
- 2024年2月至5月,当大多数下呼吸道感染由其他病毒引起时,对这些更广泛结局的估计有效性可忽略。
证据类型、等级与局限
- 证据类型:检测阴性病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现支持继续使用尼塞韦单抗,并可能有助于增强公众对免疫规划的信任。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Nirsevimab, a long-acting monoclonal antibody, demonstrated efficacy against respiratory syncytial virus (RSV)-associated lower respiratory tract infections (LRTI) in clinical trials. Postlicensure monitoring is essential to confirm these benefits in clinical settings.
OBJECTIVE: To estimate the effectiveness of nirsevimab against medically attended RSV infections in infants and to assess how effectiveness varies by disease severity, dosage, and time since immunization.
DESIGN, SETTING, AND PARTICIPANTS: This test-negative case-control study utilized inpatient, outpatient, and emergency department data from the Yale New Haven Health System. Nirsevimab-eligible infants who were tested for RSV using polymerase chain reaction between October 1, 2023, and May 9, 2024, were included. Infants with RSV-positive results were cases and infants with RSV-negative results were controls.
EXPOSURE: Nirsevimab immunization, verified through state immunization registries.
MAIN OUTCOMES AND MEASURES: Effectiveness was estimated using multivariable logistic regression, adjusting for age, calendar month, and potential confounders. Separate models examined estimated effectiveness by clinical setting, dosage, time since immunization, and severity (defined as needing high-flow oxygen or intensive care unit admission). Broader outcomes were also analyzed, including all-cause LRTI and all-cause LRTI-associated hospitalization.
RESULTS: The analytic sample included 3090 infants (1722 male [57.3%]; median [IQR] age at testing, 6.7 [3.6-9.7] months), with 680 (22.0%) RSV-positive cases and 2410 (78.0%) RSV-negative controls. Nirsevimab uptake was 10.7% (330 patients), with 21 RSV-positive cases and 309 RSV-negative controls immunized. Adjusted effectiveness was 68.4% (95% CI, 50.3%-80.8%) against medically attended RSV infection, 61.6% (95% CI, 35.6%-78.6%) against outpatient visits, and 80.5% (95% CI, 52.0%-93.5%) against hospitalizations. The highest estimated effectiveness (84.6%; 95% CI, 58.7%-95.6%) was observed against severe RSV disease. Although estimated effectiveness against RSV infections declined from 79.3% (95% CI, 63.4%-90.6%) at 2 weeks postimmunization to 54.8% (95% CI, 16.3%-74.7%) at 14 weeks postimmunization, it remained significant. Estimated effectiveness did not vary substantially by dosage. During peak RSV season, nirsevimab appeared effective against all-cause LRTI (49.4%; 95% CI, 10.7%-72.9%) and all-cause LRTI-associated hospitalizations (79.1%; 95% CI, 27.6%-94.9%). From February to May 2024, when most LRTIs were caused by other viruses, its estimated effectiveness against these broader outcomes was negligible.
CONCLUSIONS AND RELEVANCE: In this case-control study, nirsevimab provided substantial protection against RSV-associated outcomes. These findings support its continued use and provide evidence that may help boost public confidence in the immunization program.
参考来源
- Xu H, Aparicio C, Wats A, et al. Estimated Effectiveness of Nirsevimab Against Respiratory Syncytial Virus. JAMA Netw Open. 2025. PMID: 40063022. doi:10.1001/jamanetworkopen.2025.0380
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。